Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

Elias Jabbour; Guillermo Garcia-Manero; Farhad Ravandi; Stefan Faderl; Susan O'Brien; Amber Fullmer; Jorge E. Cortes; William Wierda; Hagop Kantarjian

doi:10.1016/j.clml.2012.11.001

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Susan O'Brien, Amber Fullmer, Jorge E. Cortes, William Wierda, Hagop Kantarjian

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m² over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m² over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 10³/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.

Original language	English (US)
Pages (from-to)	131-138
Number of pages	8
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	13
Issue number	2
DOIs	https://doi.org/10.1016/j.clml.2012.11.001
State	Published - Apr 2013
Externally published	Yes

Keywords

Acute myeloid leukemia
Decitabine
Myelodysplastic syndromes
Myelomonocytic leukemia
Risk factors
chronic

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2012.11.001

Cite this

Jabbour, E., Garcia-Manero, G., Ravandi, F., Faderl, S., O'Brien, S., Fullmer, A., Cortes, J. E., Wierda, W., & Kantarjian, H. (2013). Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clinical Lymphoma, Myeloma and Leukemia, 13(2), 131-138. https://doi.org/10.1016/j.clml.2012.11.001

Jabbour, E, Garcia-Manero, G, Ravandi, F, Faderl, S, O'Brien, S, Fullmer, A, Cortes, JE, Wierda, W & Kantarjian, H 2013, 'Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine', Clinical Lymphoma, Myeloma and Leukemia, vol. 13, no. 2, pp. 131-138. https://doi.org/10.1016/j.clml.2012.11.001

@article{5dcd4c02653d4c3992d99f07b562ee4d,

title = "Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine",

abstract = "Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.",

keywords = "Acute myeloid leukemia, Decitabine, Myelodysplastic syndromes, Myelomonocytic leukemia, Risk factors, chronic",

author = "Elias Jabbour and Guillermo Garcia-Manero and Farhad Ravandi and Stefan Faderl and Susan O'Brien and Amber Fullmer and Cortes, {Jorge E.} and William Wierda and Hagop Kantarjian",

note = "Funding Information: The authors thank Yvonne E. Yarker, PhD, CMPP, of Peloton Advantage LLC, for providing medical writing and editorial assistance during the preparation of this manuscript, which was funded by EISAI Inc. Funding Information: Angela Teng, MS, of EISAI Inc, conducted the statistical analyses. Dr Jabbour has received honoraria from Bristol-Myers Squibb and Novartis. Dr Ravandi has received research grants from Bayer , Bristol-Myers Squibb , Cephalon , Incyte , and Sunesis , and has performed formal advisory activities for Bayer, Cephalon, and Sunesis. Dr Cortes has received research grants from Celgene and EISAI Inc . Dr Kantarjian has received research grants from Celgene and EISAI Inc . The other authors have stated that they have no conflicts of interest.",

year = "2013",

month = apr,

doi = "10.1016/j.clml.2012.11.001",

language = "English (US)",

volume = "13",

pages = "131--138",

journal = "Clinical Lymphoma",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "2",

}

TY - JOUR

T1 - Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

AU - Jabbour, Elias

AU - Garcia-Manero, Guillermo

AU - Ravandi, Farhad

AU - Faderl, Stefan

AU - O'Brien, Susan

AU - Fullmer, Amber

AU - Cortes, Jorge E.

AU - Wierda, William

AU - Kantarjian, Hagop

N1 - Funding Information: The authors thank Yvonne E. Yarker, PhD, CMPP, of Peloton Advantage LLC, for providing medical writing and editorial assistance during the preparation of this manuscript, which was funded by EISAI Inc. Funding Information: Angela Teng, MS, of EISAI Inc, conducted the statistical analyses. Dr Jabbour has received honoraria from Bristol-Myers Squibb and Novartis. Dr Ravandi has received research grants from Bayer , Bristol-Myers Squibb , Cephalon , Incyte , and Sunesis , and has performed formal advisory activities for Bayer, Cephalon, and Sunesis. Dr Cortes has received research grants from Celgene and EISAI Inc . Dr Kantarjian has received research grants from Celgene and EISAI Inc . The other authors have stated that they have no conflicts of interest.

PY - 2013/4

Y1 - 2013/4

N2 - Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.

AB - Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.

KW - Acute myeloid leukemia

KW - Decitabine

KW - Myelodysplastic syndromes

KW - Myelomonocytic leukemia

KW - Risk factors

KW - chronic

UR - http://www.scopus.com/inward/record.url?scp=84877314620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877314620&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.11.001

DO - 10.1016/j.clml.2012.11.001

M3 - Article

C2 - 23260600

AN - SCOPUS:84877314620

VL - 13

SP - 131

EP - 138

JO - Clinical Lymphoma

JF - Clinical Lymphoma

SN - 2152-2650

IS - 2

ER -

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this